Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 3NVP-BKM120 2Bevacizumab 2trastuzumab duocarmazine 1talazoparib 1sitravatinib 1ponatinib 1niraparib 1mirvetuximab soravtansine 1lenvatinib 1dostarlimab 1dactolisib 1bemarituzumab 1Trastuzumab 1Taxes 1TAS-116 1Sevoflurane 1Radiotherapy 1Propofol 1Proflavine 1Polymerase Chain Reaction 1Paclitaxel 1PM 01183 1Methods 1Metformin 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1Letrozole 1Interviews as Topic 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Endometrial Neoplasms × trastuzumab duocarmazine × Clear all
NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

QuantumLeap Healthcare Collaborative

Phase 1 Withdrawn
BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡